<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347506">
  <stage>Registered</stage>
  <submitdate>20/09/2011</submitdate>
  <approvaldate>20/09/2011</approvaldate>
  <actrnumber>ACTRN12611001005943</actrnumber>
  <trial_identification>
    <studytitle>Can certain anaesthesia medications &amp; techniques provide additional benefits after cancer surgery apart from pain relief and speed of recovery from that surgery (LIPO trial - Lignocaine infusion given peri-operatively)</studytitle>
    <scientifictitle>Can anaesthetic technique in the form of peri-operative lignocaine infusion to blunt surgical stress response have additional benefits in long term outcome following primary cancer surgery</scientifictitle>
    <utrn />
    <trialacronym>LIPO (Lignocaine Infusion Peri-operatively)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-metastatic cancers in patients undergoing primary cancer surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intra-operative lignocaine infusion.  Replica of methodology from existing study, specifically Kuo et al, British Journal of Anaesthesia, 97 (5): 6406 (2006): 2mg/kg over 15 mins, followed by 3mg/kg/hr IV.  Continued intra-op and 30 mins post op.  Intraoperative top-up fentanyl and post operative morphine patient controlled analgesia (PCA) if required.

Additional resource [ANZCTR no: 12609001073291] 
&amp; Annals of Surgery - Volume 246, Number 2, August 2007 page 192

- slight modification in methodology &amp; dose</interventions>
    <comparator>Saline.  Intraoperative top-up fentanyl and post operative morphine patient controlled analgesia (PCA) if required.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumour recurrence.  Clinical assessments and relevant biochemical markers specific to each cancer type.</outcome>
      <timepoint>1 year, 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality.  Death register investigation, phone calls to prompt clinical assessment by surgeons, note retrieval to determine surgical outcome.  Biochemical markers relevant to the specific cancer type.</outcome>
      <timepoint>1 year, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of hospital stay, including pain, DVT, and other miscellanous surgical complications.  Recording of pain medication used, pain scores, length of stay, possible complications (free format)</outcome>
      <timepoint>Up to 1 week post operation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Non metastatic cancer requiring primary surgery:
Colectomy, nephrectomy, prostatectomy, hysterectomy, melanoma excision, mastectomy, cystectomy</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Metastases
ASA 4 and above
Diabetes
Concurrent pre-operative opioid analgesic use
Anti arrythmic drugs, arrythmogenic conditions
Hepatic or renal impairment
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patient leaflet to selected population.  
If patient willing, anaesthetist to decide if patient elligible.
Central randomisation of drug packs by pharmacy within each subgroup (cancer type - ie each cancer type has 50% intervention vs placebo)
Drug packs matched to randomisation list, placed in temp storage by pharmacy in categories (per cancer type), obtained at random by anaesthetist on day of surgery from temp storage category and pack number recorded.</concealment>
    <sequence>Double blinded, pharmacy generated centralised randomisation list by simple computer sequence generation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/10/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Palmerston North Hospital</primarysponsorname>
    <primarysponsoraddress>c/o Anaesthetic Dept
50 Ruahine St
Palmerston North
4410</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Craig Surtees</fundingname>
      <fundingaddress>c/o Anaesthetic Dept
50 Ruahine St
Palmerston North
4410</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South A Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Montgomery Watson Building
6 Hazeldean Road
Christchurch</ethicaddress>
      <ethicapprovaldate>14/09/2011</ethicapprovaldate>
      <hrec>URA/11/08/046</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Craig Surtees</name>
      <address>c/o Anaesthetic Dept
50 Ruahine St
Palmerston North
4410</address>
      <phone>+64 6 3569169</phone>
      <fax />
      <email>surtees@rocketmail.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Craig Surtees</name>
      <address>c/o Anaesthetic Dept
50 Ruahine St
Palmerston North
4410</address>
      <phone>+64 6 3569169</phone>
      <fax />
      <email>surtees@rocketmail.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Craig Surtees</name>
      <address>c/o Anaesthetic Dept
50 Ruahine St
Palmerston North
4410</address>
      <phone>+64 6 3569169</phone>
      <fax />
      <email>surtees@rocketmail.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>